Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Accenture
McKinsey
Federal Trade Commission
US Army
Boehringer Ingelheim

Generated: June 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,669,009

« Back to Dashboard

Which drugs does patent 9,669,009 protect, and when does it expire?

Patent 9,669,009 protects SPRITAM and is included in one NDA.

This patent has fifteen patent family members in nine countries.

Summary for Patent: 9,669,009
Title:Rapid disperse dosage form containing levetiracetam
Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
Inventor(s): Jacob; Jules (Yardley, PA), Coyle; Norman (Fort Washington, PA), West; Thomas G. (Lawrenceville, NJ), Monkhouse; Donald C. (Radnor, PA), Surprenant; Henry L. (Phoenixville, PA), Jain; Nemichand B. (Princeton Junction, NJ)
Assignee: Aprecia Pharmaceuticals Company (Langhorne, PA)
Application Number:15/095,785
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,669,009
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,669,009

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF ADMINISTERING LEVETIRACETAM ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Colorcon
Citi
US Department of Justice
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.